Get the Stockscreener App
5.725
0.38%
0.025
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $5.725, with a volume of 878.80K.
It is up +0.38% in the last 24 hours and up +26.31% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$5.70
Open:
$5.75
24h Volume:
878.80K
Relative Volume:
0.35
Market Cap:
$412.79M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-3.4909
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-1.35%
1M Performance:
+26.31%
6M Performance:
-24.81%
1Y Performance:
-35.49%
1-Day Range:
$5.60
$5.78
1-Week Range:
$5.49
$6.13
52-Week Range:
$3.553
$11.16
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
5.73 | 412.79M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.35 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
581.75 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
558.09 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.65 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.08 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN
Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria
Piper Sandler maintains Altimmune stock with $25 target - Investing.com
Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus
Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan
Altimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic Developments - Yahoo Finance
Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks
Earnings call transcript: Altimmune Q1 2025 results show narrower loss By Investing.com - Investing.com Canada
Altimmune, Inc. SEC 10-Q Report - TradingView
Altimmune (ALT) Advances NASH Treatment and Secures $100M Credit Facility - GuruFocus
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN
Altimmune, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALT) - Seeking Alpha
ALTI Reports Strong Q1 Revenue Growth | ALTI Stock News - GuruFocus
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News
Earnings call transcript: Altimmune Q1 2025 results show narrower loss - Investing.com Australia
Altimmune (ALT) Sees Modest Pre-Market Rise After Earnings Repor - GuruFocus
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Altimmune (ALT) Secures $100 Million Credit Facility to Advance Pemvidutide Development | ALT Stock News - GuruFocus
Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital - marketscreener.com
Altimmune (ALT) Q1 Revenue Steady as Pemvidutide Developments Pr - GuruFocus
Altimmune (ALT) Anticipates Q1 Earnings with Positive EPS Revisi - GuruFocus
Altimmune secures $100 million credit facility for drug development By Investing.com - Investing.com India
Altimmune Announces First Quarter 2025 Financial Results and Business Update - The Manila Times
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital - The Manila Times
What to Expect from Altimmune's Earnings - Nasdaq
Stifel maintains Buy on Altimmune stock with $18 target By Investing.com - Investing.com UK
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
Shareholders that lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire
FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune's (ALT) Pemvidutide Shows Promising Results in Liver Health Study | ALT Stock News - GuruFocus
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ | ALT Stock News - GuruFocus
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ - The Manila Times
Altimmune Presents Promising Analyses of Pemvidutide's Efficacy in MASH Treatment at EASL 2025 - Nasdaq
Altimmune at The Citizens JMP Life Sciences Conference: Pembidutide’s Promise - Investing.com
Altimmune to Report First Quarter 2025 Financial Results and Pro - GuruFocus
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 | ALT Stock News - GuruFocus
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - The Manila Times
Altimmune, Inc. to Announce Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Clinical-Stage Biotech Altimmune Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan
Trend Tracker for (ALT) - news.stocktradersdaily.com
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
What's Going On With Altimmune (ALT) Stock Today? - Benzinga
Press Release Distribution & PR Platform - ACCESS Newswire
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 - The Manila Times
Altimmune, Inc. to Showcase Novel MASH Resolution Index Data for Pemvidutide at EASL International Liver Congress™ 2025 - Nasdaq
Altimmune to Participate in the Citizens Life Sciences Conferenc - GuruFocus
Altimmune to Participate in the Citizens Life Sciences Conference - The Manila Times
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):